Pendium

Step 1 of 9

WINLEVI owns the 'topical androgen' niche, but loses ground in general acne conversations.

You are currently the default recommendation for specific hormonal acne queries, but you are nearly invisible in broader category discovery.

WINLEVI's baseline score
42/100
Moderate

WINLEVI has solid visibility among high-intent medical queries but is overshadowed by legacy treatments in general acne prompts. The brand's strength lies in its unique mechanism of action, which AI agents recognize as a distinct category.

What we see
  • WINLEVI has strong visibility in medical and 'new drug' discovery prompts due to its unique FDA status.
  • The brand is frequently omitted in general 'best acne cream' queries which are dominated by OTC brands like Differin.
  • There is a visible gap in content that addresses the 'how to use' aspect which AI agents often struggle to explain accurately.
  • Competition from generic spironolactone (oral) is a major hurdle in AI recommendations for hormonal acne.
  • YouTube dermatologists (Dr. Dray, etc.) have a significant influence on how Gemini perceives the brand.
Business goals WINLEVI is likely trying to hit
  • Increase physician prescriptions for hormonal acne cases
  • Differentiate clascoterone from traditional retinoid-based treatments
  • Drive patient inquiries during dermatology consultations
  • Establish the brand as the first-choice topical androgen receptor inhibitor